Home » Stocks » AXDX

Accelerate Diagnostics, Inc. (AXDX)

Stock Price: $7.39 USD 0.10 (1.30%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $7.40 +0.01 (0.14%) May 7, 4:37 PM
Market Cap 456.78M
Revenue (ttm) 11.17M
Net Income (ttm) -78.21M
Shares Out 56.01M
EPS (ttm) -1.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $7.39
Previous Close $7.30
Change ($) 0.10
Change (%) 1.30%
Day's Open 7.35
Day's Range 7.15 - 7.68
Day's Volume 273,162
52-Week Range 6.82 - 19.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -24.24% and -29.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

TUCSON, Ariz., May 6, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2021.

1 day ago - PRNewsWire

TUCSON, Ariz., May 5, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that management will host a conference call on Thursday, May 6, 2021 at 4:30 p.m.

2 days ago - PRNewsWire

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

TUCSON, Ariz., Feb. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2020. "We were pleased ...

2 months ago - PRNewsWire

TUCSON, Ariz., Jan. 12, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the fourth quarter and full year ending December 31, 2020. High...

3 months ago - PRNewsWire

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

TUCSON, Ariz., Nov. 5, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2020. "We achieved solid revenue growt...

6 months ago - PRNewsWire

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

TUCSON, Ariz., Aug. 24, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.

8 months ago - PRNewsWire

This new testing platform will speed up health checks by determining whether asymptomatic people have COVID-19 antibodies in 30 minutes.

8 months ago - The Motley Fool

TUCSON, Ariz., Aug. 18, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.

8 months ago - PRNewsWire

Accelerate Diagnostics (AXDX) CEO Jack Phillips on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

TUCSON, Ariz., Aug. 6, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.

9 months ago - PRNewsWire

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

11 months ago - Zacks Investment Research

Accelerate Diagnostics (AXDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns.

Other stocks mentioned: CDLX, GIII, NGM, OPK
1 year ago - InvestorPlace

Daily Insider Ratings Round Up 4/1/20

Other stocks mentioned: CWEN, FPH, IFF, MGM, MYOV, NCMI, XPO
1 year ago - Seeking Alpha

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Two of the sector's biggest winners of the past 10 years are still flying under the radar. Which looks like the better buy today?

Other stocks mentioned: SLP
1 year ago - The Motley Fool

Which biotech was a 37-bagger?

Other stocks mentioned: ABMD, ACAD, DXCM, EXAS, JAZZ, NBIX, NEO ...
1 year ago - The Motley Fool

Accelerate Diagnostics, Inc. (AXDX) CEO Larry Mehren on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.13% and -27.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Finally, reaching a positive inflection point for devices under contract.

1 year ago - Seeking Alpha

Accelerate Diagnostics' (AXDX) CEO Larry Mehren on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.00% and -33.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Accelerate Diagnostics, Inc. (AXDX) CEO Lawrence Mehren on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.98% and -17.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About AXDX

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic sus... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 18, 1996
CEO
John Phillips
Employees
224
Stock Exchange
NASDAQ
Ticker Symbol
AXDX
Full Company Profile

Financial Performance

In 2020, AXDX's revenue was $11.17 million, an increase of 20.09% compared to the previous year's $9.30 million. Losses were -$78.21 million, -7.23% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for AXDX stock is "Buy." The 12-month stock price forecast is 12.33, which is an increase of 66.85% from the latest price.

Price Target
$12.33
(66.85% upside)
Analyst Consensus: Buy